Pipeline and Clinical Trials - Corcept Therapeutics

A PIPELINE BUILT TO MEET PATIENTS’ NEEDS.

Our global infrastructure of ongoing trials and studies is thriving. See our work to help find new treatments for serious diseases.

Hypercortisolism (Cushing Syndrome)

Target Indication (Study Name)

Compound

Phase I

Phase II

Phase III

Phase IV

Endogenous Cushing syndrome (GRACE)

Relacorilant

PHASE III

Phase III

FILED

Hypercortisolism associated with adrenal adenoma or hyperplasia (GRADIENT)

Relacorilant

PHASE III

Phase III

FILED

Extension study to evaluate long term safety

Relacorilant

PHASE III

Phase II

FILED

Prevalence and treatment of hypercortisolism in patients with type 2 diabetes (CATALYST)

Korlym

PHASE IV

Phase IV

Prevalence of endogenous hypercortisolism in patients with resistant hypertension (MOMENTUM)

PHASE IV

Phase IV

Oncology

Target Indication (Study Name)

Compound

Phase I

Phase II

Phase III

Phase IV

Platinum-resistant ovarian cancer (ROSELLA)

Relacorilant + Abraxane (nab-paclitaxel)

PHASE III

Phase III

FILED

Platinum-resistant ovarian cancer (BELLA Arm A)

Relacorilant + Abraxane (nab-paclitaxel) + Avastin (bevacizumab)

PHASE II

Phase II

Platinum-sensitive ovarian cancer with disease progression on PARP inhibitor (BELLA Arm B)

Relacorilant + Abraxane (nab-paclitaxel) + Avastin (bevacizumab)

PHASE II

Phase III

2/3L Endometrial cancer (BELLA Arm C)

Relacorilant + Abraxane (nab-paclitaxel)

PHASE II

Phase II

Prostate cancer

Relacorilant + Xtandi (enzalutamide)¹

PHASE II

Phase II

Neurology

Target Indication (Study Name)

Compound

Phase I

Phase II

Phase III

Phase IV

ALS (DAZALS)

Dazucorilant

PHASE II

Phase II

METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS / NON-ALCOHOLIC STEATOHEPATITIS

Target Indication (Study Name)

Compound

Phase I

Phase II

Phase III

Phase IV

MASH/NASH

Miricorilant

PHASE II

Phase II

Additional Areas of Research

Diabetes

Anxiety

Antipsychotic-Induced Weight Gain

Hypertension

Obesity

Addiction

Non-Small Cell Lung Cancer

Neurodegenerative Diseases

Osteoporosis

Central Serous Chorioretinopathy

Psychiatry

Metabolic-Associated Fatty Liver Disease / Non-Alcoholic Fatty Liver Disease

MASH: metabolic dysfunction-associated steatohepatitis. NASH: non-alcoholic steatohepatitis. ALS: amyotrophic lateral sclerosis.

¹Investigator-sponsored trial, University of Chicago

Explore Clinical Trials

Learn more about the design and status of current Corcept-sponsored clinical trials and find contact information for investigators.

Learn More

A PIPELINE BUILT TO MEET PATIENTS’ NEEDS.

Hypercortisolism (Cushing Syndrome)

Target Indication (Study Name)

Compound

Phase I

Phase II

Phase III

Phase IV

Endogenous Cushing syndrome (GRACE)

Relacorilant

PHASE III

Hypercortisolism associated with adrenal adenoma or hyperplasia (GRADIENT)

Relacorilant

PHASE III

Extension study to evaluate long term safety

Relacorilant

PHASE III

Prevalence and treatment of hypercortisolism in patients with type 2 diabetes (CATALYST)

Korlym

PHASE IV

Prevalence of endogenous hypercortisolism in patients with resistant hypertension (MOMENTUM)

PHASE IV

Oncology

Target Indication (Study Name)

Compound

Phase I

Phase II

Phase III

Phase IV

Platinum-resistant ovarian cancer (ROSELLA)

Relacorilant + Abraxane (nab-paclitaxel)

PHASE III

Platinum-resistant ovarian cancer (BELLA Arm A)

Relacorilant + Abraxane (nab-paclitaxel) + Avastin (bevacizumab)

PHASE II

Platinum-sensitive ovarian cancer with disease progression on PARP inhibitor (BELLA Arm B)

Relacorilant + Abraxane (nab-paclitaxel) + Avastin (bevacizumab)

PHASE II

2/3L Endometrial cancer (BELLA Arm C)

Relacorilant + Abraxane (nab-paclitaxel)

PHASE II

Prostate cancer

Relacorilant + Xtandi (enzalutamide)1

PHASE II

Neurology

Target Indication (Study Name)

Compound

Phase I

Phase II

Phase III

Phase IV

ALS (DAZALS)

Dazucorilant

PHASE II

METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS / NON-ALCOHOLIC STEATOHEPATITIS

Target Indication (Study Name)

Compound

Phase I

Phase II

Phase III

Phase IV

MASH/NASH

Miricorilant

PHASE II

Additional Areas of Research

Explore Clinical Trials

Relacorilant + Xtandi (enzalutamide)¹